On Friday, Fate Therapeutics Inc (NASDAQ: FATE) opened lower -3.66% from the last session, before settling in for the closing price of $0.88. Price fluctuations for FATE have ranged from $0.83 to $7.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 46.37% annually for the last half of the decade. Company’s average yearly earnings per share was noted 4.69% at the time writing. With a float of $103.48 million, this company’s outstanding shares have now reached $113.93 million.
In an organization with 181 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -189.23%, operating margin of -1542.63%, and the pretax margin is -1366.46%.
Fate Therapeutics Inc (FATE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Fate Therapeutics Inc is 9.70%, while institutional ownership is 85.12%. The most recent insider transaction that took place on Mar 06 ’25, was worth 104,881. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,980 for $1.55, making the entire transaction worth $9,269. This insider now owns 270,203 shares in total.
Fate Therapeutics Inc (FATE) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.44% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Check out the current performance indicators for Fate Therapeutics Inc (FATE). In the past quarter, the stock posted a quick ratio of 7.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Let’s dig in a bit further. During the last 5-days, its volume was 1.33 million. That was inferior than the volume of 2.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.12%. Additionally, its Average True Range was 0.09.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 0.60%, which indicates a significant decrease from 8.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.32% in the past 14 days, which was lower than the 105.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1705, while its 200-day Moving Average is $2.6487. However, in the short run, Fate Therapeutics Inc’s stock first resistance to watch stands at $0.8819. Second resistance stands at $0.9144. The third major resistance level sits at $0.9379. If the price goes on to break the first support level at $0.8259, it is likely to go to the next support level at $0.8024. The third support level lies at $0.7699 if the price breaches the second support level.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
There are currently 114,597K shares outstanding in the company with a market cap of 97.33 million. Presently, the company’s annual sales total 13,630 K according to its annual income of -186,260 K. Last quarter, the company’s sales amounted to 1,860 K and its income totaled -52,150 K.
